Your browser doesn't support javascript.
loading
Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer.
Gerber, David E; Camidge, D Ross; Morgensztern, Daniel; Cetnar, Jeremey; Kelly, Ronan J; Ramalingam, Suresh S; Spigel, David R; Jeong, Woondong; Scaglioni, Pier P; Zhang, Song; Li, Marilyn; Weaver, David T; Vaikus, Louis; Keegan, Mitchell; Horobin, Joanna C; Burns, Timothy F.
Afiliação
  • Gerber DE; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Mail Code 8852, Dallas, TX 75390-8852, USA. Electronic address: david.gerber@utsouthwestern.edu.
  • Camidge DR; University of Colorado Denver, 1665 Aurora Ct, Aurora, CO 80045, USA. Electronic address: ross.camidge@ucdenver.edu.
  • Morgensztern D; Washington University School of Medicine, 660 S. Euclid Avenue, St. Louis, MO 63110, USA. Electronic address: dmorgens@dom.wustl.edu.
  • Cetnar J; Oregon Health & Science University, 3181 SW Sam Jackson Park Rd, Portland, OH 97239, USA. Electronic address: cetnarj@ohsu.edu.
  • Kelly RJ; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 201 N Broadway St., Baltimore, MD 21287, USA. Electronic address: ronan.kelly@BSWHealth.org.
  • Ramalingam SS; Winship Cancer Institute of Emory University, Atlanta, GA 30322, USA. Electronic address: suresh.ramalingam@emory.edu.
  • Spigel DR; Sarah Cannon Research Institute, 250 25th Ave N Ste 200, Nashville, TN 37203, USA. Electronic address: david.spigel@sarahcannon.com.
  • Jeong W; University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA.
  • Scaglioni PP; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Mail Code 8852, Dallas, TX 75390-8852, USA. Electronic address: SCAGLIPR@ucmail.uc.edu.
  • Zhang S; Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Mail Code 8852, Dallas, TX 75390-8852, USA. Electronic address: song.zhang@utsouthwestern.edu.
  • Li M; Baylor College of Medicine, 1 Baylor Plaza, Houston, TX 77030, USA.
  • Weaver DT; Verastem, Inc., 117 Kendrick Street, Suite 500, Needham, MA 02494, USA. Electronic address: dweaver@verastem.com.
  • Vaikus L; Verastem, Inc., 117 Kendrick Street, Suite 500, Needham, MA 02494, USA. Electronic address: lvaikus@verastem.com.
  • Keegan M; Verastem, Inc., 117 Kendrick Street, Suite 500, Needham, MA 02494, USA. Electronic address: mitch@bostonpharmaceuticals.com.
  • Horobin JC; Verastem, Inc., 117 Kendrick Street, Suite 500, Needham, MA 02494, USA. Electronic address: jhorobin@iderapharma.com.
  • Burns TF; University of Pittsburgh Medical Center Hillman Cancer Center, University of Pittsburgh, 5117 Centre Avenue, Pittsburgh, PA 15213, USA. Electronic address: burnstf@upmc.edu.
Lung Cancer ; 139: 60-67, 2020 01.
Article em En | MEDLINE | ID: mdl-31739184

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirazinas / Sulfonamidas / Benzamidas / Proteínas Proto-Oncogênicas p21(ras) / Carcinoma Pulmonar de Células não Pequenas / Resistencia a Medicamentos Antineoplásicos / Adenocarcinoma de Pulmão / Neoplasias Pulmonares / Mutação Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirazinas / Sulfonamidas / Benzamidas / Proteínas Proto-Oncogênicas p21(ras) / Carcinoma Pulmonar de Células não Pequenas / Resistencia a Medicamentos Antineoplásicos / Adenocarcinoma de Pulmão / Neoplasias Pulmonares / Mutação Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article